Completed NA INTERVENTIONAL 2-arm NCT00130325

A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts (IRS)

A Double Blind Placebo-controlled Randomized Trial of Isoniazid for the Reversion of a Positive IFNg ELISPOT in TB Case Contacts

Sponsor: Medical Research Council Unit, The Gambia

Conditions Tuberculosis

Interventions Isoniazid Placebo of Isoniazid tablets 300mg

Updated 6 times since 2017 Last updated: Jan 12, 2010 Started: Oct 31, 2004 Primary completion: Oct 31, 2008 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00130325, this NA trial focuses on Tuberculosis and remains completed. Sponsored by Medical Research Council Unit, The Gambia, it has been updated 6 times since 2004, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical Research Council Unit, The Gambia

Data source: Medical Research Council Unit, The Gambia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Banjul, The Gambia